Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 5, 2015, Pages

  Ori, Rasmita ^a   Amos, Taryn ^a   Bergman, Hanna ^b   Soares Weiser, Karla ^b   Ipser, Jonathan C ^a   Stein, Dan J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Enhance Reviews Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; PLACEBO;

AGORAPHOBIA; ANXIETY DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE BEHAVIORAL THERAPY; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPOSURE AND RESPONSE PREVENTION THERAPY; EXPOSURE THERAPY; HUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROLONGED EXPOSURE THERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SOCIAL PHOBIA; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; VIRTUAL REALITY EXPOSURE THERAPY; ADOLESCENT; ADULT; AGED; ANXIETY DISORDERS; CHILD; COGNITIVE THERAPY; META ANALYSIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDERS; CHILD; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; CYCLOSERINE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84941901144     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007803.pub2     Document Type: Review

References (165)

1. Cameron JA. Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia NCT00128401. ClinicalTrials.gov [www.clinicaltrials.gov] 2005 (accessed on 26 June 2014).
2. De Kleine RA, Hendriks G-J, Kusters WJC, Broekman TG, Van Minnen A. A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biological Psychiatry 2012;71(11):962-8.
3. de Kleine RA, Hendriks GJ, Smits JA, Broekman TG, van Minnen A. Prescriptive variables for d-cycloserine augmentation of exposure therapy for posttraumatic stress disorder. Journal of Psychiatric Research 2014;48(1):40-6.
4. van Minnen A. Augmentation of (imaginal) exposure therapy with D-cycloserine for patients with Posttraumatic Stress Disorder (PTSD); A Randomized Placebo controlled Study. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=NTR1184] 2007.
5. Difede J. Combined Exposure Therapy and D-Cycloserine vs. Placebo for Posttraumatic Stress Disorder. ClinicalTrials.gov [http://clinicaltrials.gov/show/NCT00632632] 2005 (accessed on 26 June 2014).
6. Difede J, Cukor J, Wyka K, Olden M, Hoffman H, Lee FS, Altemus M. D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology 2014;39(5):1052-8.
7. Farrell L. A randomised controlled trial to evaluate the effects of D-Cycloserine in combination with Exposure Therapy, versus pill placebo and Exposure Therapy, in the treatment of refractory pediatric Obsessive-Compulsive Disorder (OCD) to improve the severity of obsessive-compulsive (OC) symptoms. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=ACTRN12609000370202] 2009 (accessed on 26 June 2014).
8. Farrell LJ, Waters AM, Boschen MJ, Hattingh L, McConnell H, Milliner EL, et al. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy. Journal of Depression and Anxiety 2013;30(8):723-31.
9. Guastella A. A randomised controlled trial to evaluate the effect of D-Cycloserine in combination with exposure therapy in the treatment of social phobia to improve the severity of social phobia symptoms. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=ACTRN12606000352505] 2006 (accessed on 26 June 2014).
10. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biological Psychiatry 2008;63(6):544-9.
11. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Archives of General Psychiatry 2006;63(3):298-304.
12. Hofmann SG, Pollack MH, Smits JA. D-cycloserine Enhancement of Exposure in Social Phobia. ClinicalTrials.gov [http://clinicaltrials.gov/show/NCT00515879] 2007 (accessed on 26 June 2014).
13. Hofmann SG, Smits JA, Rosenfield D, Simon N, Otto MW, Meuret AE, et al. D-cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. American Journal of Psychiatry 2013;170(7):751-8.
14. NCT00633984 D-Cycloserine Enhancement of Exposure in Social Phobia. ClinicalTrials.gov [http://clinicaltrials.gov/show/NCT00633984] 2008 (accessed on 26 June 2014).
15. Pollack MH, Smits J, Simon NM, Meuret A, Marques L, Otto MW, et al. D-Cycloserine (DCS) augmentation of CBT for social anxiety disorder: Results from an RCT abstract. Biological Psychiatry. Abstracts of the 67th annual scientific convention and meeting of the Society of Biological Psychiatry May 3-5, 2012. Philadelphia, PA United States, 2012; Vol. 71:555.
16. Smits J. Session success moderates the efficacy of cognitive enhancers for improving exposure therapy outcomes [conference abstract]. Biological Psychiatry 2014;75(9 Suppl 1):30S.
17. Smits JA, Hofmann SG, Rosenfield D, DeBoer LB, Costa PT, Simon NM, et al. D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. Journal of Consulting Psychology 2013;81(6):1100-12.
18. Smits JA, Rosenfield D, Otto MW, Marques L, Davis ML, Meuret AE, et al. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. Journal of Psychiatric Research 2013;47(10):1455-61.
19. Zalta AK, Dowd S, Rosenfield D, Smits JA, Otto MW, Simon NM, et al. Sleep quality predicts treatment outcome in CBT for social anxiety disorder. Journal of Depression and Anxiety 2013;30(11):1114-20.
20. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, et al. D-cycloserine augmentated exposure therapy for obsessive-compulsive disorder. Biological Psychiatry 2007;62(9):835-8.
21. Litz BT. A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD. ClinicalTrials.gov [http://clinicaltrials.gov/show/NCT00371176] 2006 (accessed 26 June 2014).
22. Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, Otto MW, Hofmann SG. A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. Journal of Psychiatric Reseach 2012;46:1184-90.
23. Euctr-006947-38-Gb A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorder. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2008-006947-38-GB] 2009 (accessed on 26 June 2014)
24. Mataix-Cols D, Turner C, Monzani B, Isomura K, Murphy C, Krebs G, Heyman I. Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: Pilot randomised controlled trial. British Journal of Psychiatry 2014;204(1):77-8.
25. NCT01450306 Exposure, D-cycloserine Enhancement, and fMRI in Snake Phobics. ClinicalTrials.gov [http://clinicaltrials.gov/show/NCT01450306] 2010 (accessed on 26 June 2014).
26. Nave AM, Tolin DF, Stevens MC. Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study. Journal of Clinical Psychiatry 2012;73(9):1179-86.
27. Otto MW. Placebo-Controlled Evaluation of the Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Panic Disorder. ClinicalTrials.gov [http://clinicaltrials.gov/show/NCT00131339] 2004 (accessed on 26 June 2014).
28. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, et al. Efficacy of d-cycloserine for enhancing response to Cognitive-Behaviour Therapy for Panic Disorder. Biological Psychiatry 2010;67(4):365-70.
29. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry 2004;61(11):1136-44.
30. Granoff AL. The impact of benzodiazepine management in the randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy [letter]. American Journal of Psychiatry 2014;171(11):1222. [Other comments/author response in: 'letters to the editor', http://ajp.psychiatryonline.org/toc/ajp/171/11]
31. Jovanovic T, Norrholm S, Gerardi M, Breazeale K, Davis M, Duncan E, et al. Psychophysiological and cortisol reactivity predicts PTSD treatment outcome in virtual reality exposure therapy with D-cycloserine. Neuropsychopharmacology [abstracts of the 53rd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2014 Dec 7-11; Phoenix, AZ United States] 2014:S369-70.
32. Rothbaum BO. D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD. http://clinicaltrials.gov/show/NCT00356278 2006.
33. Rothbaum BO, Price M, Jovanovic T, Norrholm SD, Gerardi M, Dunlop B, et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. American Journal of Psychiatry 2014;171(6):640-8.
34. Scheeringa MS. Effect of D-cycloserine on Treatment of PTSD in Youth. ClinicalTrials.gov [http://www.clinicaltrials.gov/ct2/results?term=NCT01157416&Search=Search] 2010 (accessed on 26 June 2014).
35. Scheeringa MS, Weems CF. Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress. Journal of Child and Adolescent Psychopharmacology 2014;24(2):69-77.
36. Sheerin CM. Slope of change through D-cycloserine facilitation of exposure therapy in a social anxiety population. Dissertation Abstracts International: Section B: the Sciences and Engineering Dissertation Abstracts International 2014 75(6-B(E)) 2014.
37. Arolt V, Zwanzger P, Ströhle A, Hamm A, Gerlach A, Kircher T, Deckert J. The research network PANIC-NET: improving the treatment of panic disorder - from a better understanding of fear circuit mechanisms to more effective psychological treatment and routine care. Psychotherapie, Psychosomatik, Medizinische Psychologie 2009;59(3):124-31.
38. Siegmund A, Golfels F, Finck C, Halisch A, Rath D, Plag J, Strohle A. D-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. Journal of Psychiatric Research 2011;45(8):1042-7.
39. Strohle A. D-cycloserine-supported exposure in patients with panic disorder. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=ISRCTN44960833] 2007 (accessed on 26 June 2014).
40. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology 2007;22(4):230-7.
41. Park JM, Small BJ, Geller DA, Murphy TK, Lewin AB, Storch EA. Does D-cycloserine augmentation of CBT improve therapeutic homework compliance for pediatric obsessive-compulsive disorder?. Journal of Child and Family Studies 2014;23(5):863-71.
42. Storch E. D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder. ClinicaTrials.gov [http://clinicaltrials.gov/show/NCT00864123] 2008 (accessed 26 June 2014).
43. Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, Henin A, et al. A preliminary study of d-cycloserine augmentation of cognitive-behavioural therapy in pediatric obsessive-compulsive disorder. Biological Psychiatry 2010;68(11):1073-6.
44. Smits JA, Rosenfield D, Otto MW, Powers MB, Hofmann SG, Telch MJ, et al. D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: Evidence from the treatment of height phobia. Biological Psychiatry 2013;73(11):1054-8.
45. Tart CA, Handelsman PR, DeBoer LB, Rosenfield D, Pollack MH, Hofmann SG, et al. Augmentation of exposure therapy with post-session administration of d-cycloserine. Journal of Psychiatric Research 2013;47(2):168-74.
46. Chasson GS, Buhlmann U, Tolin DF, Rao SR, Reese HE, Rowley T, et al. Need for speed: Evaluating the slopes of OCD recovery in behaviour therapy enhanced with D-cycloserine. Behavioural Research and Therapy 2010;48(7):675-9.
47. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, et al. Augmentation of behaviour therapy with d-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry 2008;165(3):335-41.
48. Wilhelm S, Tolin D. A Randomized, Double-blind, Placebo-controlled Medication Trial With D-Cycloserine for Individuals With Obsessive-compulsive Disorder Currently Receiving Behavior Therapy. ClinicalTrials.gov [http://clinicaltrials.gov/show/NCT00126282] 2003 (accessed on 26 June 2014).
49. Behar E, McHugh RK, Peckham A, Otto MW. D-cycloserine for the augmentation of an attentional training intervention for trait anxiety. Journal of Anxiety Disorders 2010;24(4):440-5.
50. Evins AE. Cognitive remediation with D-cycloserine added to cue exposure therapy. 51st Annual Meeting of the American College of Neuropsychopharmacology, Acnp; 2012 Feb 2-6; Hollywood, FL United States. 2012.
51. Galovic N, Rapee R. The effect of D-Cycloserine on imaginal and in-vivo exposure therapy for public speaking anxiety. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=ACTRN12610000587000] 2010.
52. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R. A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. Journal of Psychiatric Research 2007;41(6):466-71.
53. Guastella A, Lovibond PF, Dadds MR, Mitchell P, Richardson R. A randomised control trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behaviour Research and Therapy 2007;45(4):663-72.
54. Gutner CA, Weinberger J, Hofmann SG. The effect of D-cycloserine on subliminal cue exposure in spider fearful individuals. Cognitive Behaviour Therapy 2012;41(4):335-44.
55. Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M, Cohen T. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. International Journal of Neuropsychopharmacology 2002;5(4):301-7.
56. Inslicht SS, Metzler TJ, Garcia NM, Pineles SL, Milad MR, Orr SP, et al. Sex differences in fear conditioning in posttraumatic stress disorder. Journal of Psychiatric Research 2013;47(1):64-71.
57. Levinson CA. A Double Blind Clinical Trial of DCS for Food Anxiety for Patients With Anorexia and Bulimia Nervosa. http://clinicaltrials.gov/show/NCT01996644 2013.
58. NCT00257361 D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder. ClinicalTrials.gov [http://clinicaltrials.gov/show/NCT00257361] 2005.
59. Attari A, Rajabi F, Maracy MR. D-cycloserine for treatment of numbing and avoidance in chronic post traumatic stress disorder: A randomized, double blind, clinical trial. Journal of Research in Medical Sciences 2014;19(7):592-8.
60. Rajabi F. Efficacy of D-Cycloserine for Treatment of Numbing and Avoidance in patients with Chronic PTSD - D-Cycloserine for Numbing and Avoidance in Chronic PTSD. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/] 2013.
61. Rodebaugh TL, Levinson CA, Lenze EJ. A high-throughput clinical assay for testing drug facilitation of exposure therapy. Depression and Anxiety 2013; Vol. 30:631-7.
62. Sharp WG. Use of D-cycloserine to Facilitate Extinction of Food Aversion in Pediatric Populations. http://clinicaltrials.gov/show/NCT01923896 2013.
63. Steinglass J, Sysko R, Schebendach J, Broft A, Strober M, Walsh BT. The application of exposure therapy and D-cycloserine to the treatment of anorexia nervosa: a preliminary trial. Journal of Psychiatric Research 2007;13(4):238-45.
64. Cath DC. D-cycloserine enhancement of exposure and response prevention therapy in OCD and panic disorder with agoraphobia: a randomised controlled trial. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2050 2009.
65. Euctr-021198-35-Nl D-cycloserine (DCS) enhancement of exposure therapy in panic disorder with agoraphobia: a randomized controlled trial - D-cycloserine enhancement of exposure therapy. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2010-021198-35-NL] 2010 (accessed on 26 June 2014).
66. Klein Hofmeijer M, Duits P, Rijkeboer MM, Hoogendoorn A, Van Megen H, Van Balkom AJLM, et al. D-Cycloserine enhancement in exposure therapy for patients with a panic disorder with agoraphobia; a randomised controlled trial. European Neuropsychopharmacology 2014 S617 [abstracts of the 27th European College of Neuropsychopharmacology, ECNP Congress; 2014 Oct 18-21; Berlin Germany] 2014.
67. Cath DC. D-cycloserine enhancement of exposure and response prevention therapy in OCD and panic disorder with agoraphobia: a randomised controlled trial. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2050 2009.
68. Guay S. RCT of CBT combined with d-cycloserine for treating PTSD or comparative study of the efficacy of a cognitive-behavioral therapy for post-traumatic stress disorder with or without d-cycloserine NCT00452231. Clinicaltrials.gov [www.clinicaltrials.gov] 2007.
69. Strohle A. Augmentation of Exposure Therapy With D-Cycloserine in Patients With Agoraphobia With or Without Panic Disorder. http://clinicaltrials.gov/show/NCT01928823 2011.
70. Arman S, Soheilimehr A. The efficacy of augment of D-cycloserine and cognitive-behavioral therapy on symptoms improvement in the adolescents with one type of anxiety disorders: A double-blind randomized controlled trial. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=IRCT2012071610297N1] 2013.
71. Bergman L. The Use of D-Cycloserine to Augment Intensive Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder. http://clinicaltrials.gov/show/NCT01687140 2012.
72. Meerkanten GGZ. The effect of the addition of D-cycloserine to exposure sessions in the treatment of patients with obsessive-compulsive disorder. A randomized, placebo-controlled trial. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2007-000367-18-NL] 2007.
73. de Leeuw AS. The effect of the addition of D-cycloserine to exposure sessions in the treatment of patients with obsessive-compulsive disorder. A randomized, placebo-controlled trial [Onderzoek naar het effect van de toevoeging van D-cycloserine aan exposure sessies bij de behandeling van patiënten met een obsessieve-compulsieve stoornis]. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1189 2008.
74. Difede J. D-cycloserine Enhanced Imaginal ExposureTherapy for Posttraumatic Stress Disorder (PTSD). http://clinicaltrials.gov/show/NCT00875342 2009.
75. Difede J. Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer. http://clinicaltrials.gov/show/NCT01352637 2011.
76. Farrell L. A randomised controlled trial to evaluate the effects of D-cycloserine in combination with exposure therapy, versus pill placebo and exposure therapy, in the treatment of pediatric Specific Phobia to improve symptoms of anxiety, fear and phobic avoidance. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=ACTRN12612000420842] 2012.
77. Farrell I. A randomised controlled trial to evaluate the effects of D-cycloserine in combination with intensive exposure therapy, versus pill placebo in combination with intensive exposure therapy in the treatment of pediatric Obsessive Compulsive Disorder to improve the severity of obsessive compulsive symptoms. http://www.anzctr.org.au/ACTRN12614000140651.aspx 2014.
78. Geller DA. 2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD. http://clinicaltrials.gov/show/NCT01404208 2011.
79. Guastella A. A randomised controlled trial to evaluate the effects of D-Cycloserine in combination with Exposure Therapy in the treatment of panic disorder to improve the severity of Panic Symptoms. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=ACTRN12606000351516] 2006.
80. Otto MW, Tolin DF, Pollack MH. Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder. http://clinicaltrials.gov/show/NCT00790868 2008.
81. Pollack M, Hofmann S, Smits JA. Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder. http://clinicaltrials.gov/show/NCT02066792 2014.
82. Rapee R, Byrne S. Among Spider and Dog Phobic Children is D-Cycloserine Augmented Exposure Therapy more Effective than Exposure Therapy alone as Measured by Performance on Behavioural Approach Tests. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=ACTRN12610000490077] 2010.
83. Rapee R. D-cycloserine vs placebo combined with in-vivo exposure in the reduction of specific fears among children with broad-based anxiety disorders. WHO International Clinical Trials Registry Platform [http://apps.who.int/trialsearch/Trial.aspx?TrialID=ACTRN12611000660987] 2011.
84. Reinecke A, Harmer C. The Effect of a Single-dose of D-cycloserine on the Basic Effects of Cognitive-behaviour Therapy for Panic Disorder - a Randomized Placebo-controlled Trial. http://clinicaltrials.gov/show/NCT01680107 2012.
85. Ruck C. Internet-based Cognitive Behavior Therapy in Combination With D-Cycloserine for Obsessive Compulsive Disorder: A Double Blinded Randomized Controlled Trial. http://clinicaltrials.gov/show/NCT01649895 2012.
86. Sirbu C, Kerr PL. D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights. http://clinicaltrials.gov/show/NCT01037101 2009.
87. Smits JA. Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine. http://clinicaltrials.gov/show/NCT01944423 2013.
88. Storch EA. 1/2 D-cycloserine Augmentation of CBT for Pediatric OCD. http://clinicaltrials.gov/show/NCT01411774 2011.
89. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica 2004;420:21-7.
90. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd Edition. Washington, DC: American Psychiatric Association, 1980.
91. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994.
92. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th Edition. Washington, DC: American Psychiatric Association, 2000.
93. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing, 2013.
94. Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. International Journal of Neuropsychopharmacology 2011;14(5):697-710.
95. Bandelow B, Ruther E. Treatment-resistant panic disorder. CNS Spectrums 2004;9(10):725-39.
96. Bandelow B, Zohar J, Hollander E, Kasper S, Möller H. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders. Informa Healthcare 2008;9(4):248-312.
97. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000;283(19):2529-36.
98. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561-71.
99. Beck AT, Steer RA. Beck Anxiety Inventory. San Antonio, TX: The Psychological Corporation, 1993.
100. Beck JS, Beck AT, Jolly JB. Beck Youth Inventories. San Antonio, TX: Psychological Corporation, 2001.
101. Birmaher B, Khetarpal S, Cully M, Brent DA, McKenzie S. Screen for Child Anxiety Related Disorders (SCARED)-Parent form and child form (8 years and older). Innovations in Clinical Practice: Focuson Children & Adolescents, edited by L. VandeCreek and T.L. Jackson. Sarasota, FL: Professional Resource Press/Professional Resource Exchange, 99-104, 2003.
102. Black DW. Efficacy of combined pharmacotherapy and psychotherapy versus monotherapy in the treatment of anxiety disorders. CNS Spectrums 2006;11(10 Suppl 12):29-33.
103. Blake DD, Weathers FW, Nagy LM, et al. A clinician rating scale for assessing current and lifetime PTSD: The CAPS-1. Behavior Therapy 1990;21:187-8.
104. Boje KM, Wong G, Skolnick P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Research 1993;603(2):207-14.
105. Bontempo A, Panza KE, Bloch MH. D-cycloserine augmentation of behaviour therapy for treatment of anxiety disorders: Meta-analysis. Journal of Clinical Psychiatry 2012;73(4):533-7.
106. Brown TA, Di Nardo PA, Barlow DH. Anxiety Disorders Interview Schedule for DSM-IV. Albany, New York: University of Albany, 1989.
107. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Canadian Journal of Psychiatry 2006;51(8 Suppl 2):9S-91S.
108. Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of d-cycloserine on extinction: translation from preclinical to clinical work. Biological Psychiatry 2006;60:369-75.
109. Deeks J, Higgins JPT, Altman D. editors. Analysing and presenting results. In: Higgins JPT, Green S editor(s). Cochrane Reviewers Handbook 5.0.0 [updated February] Section 9;. Chichester, UK: John Wiley & Sons, Ltd., 2008.
110. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March2011]. The Cochrane Collaboration, 2011.
111. Difede J, Cukor J, Wyka K, Olden M, Hoffman H, Lee FS, Altemus M. D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology 2014;39(5):1052-8.
112. Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective information. Psychological Bulletin 1986;99(1):20-35.
113. Foa EB, Johnson KM, Feeny NC, Treadwell KRH. The child PTSD symptom scale (CPSS): A preliminary examination of its psychometric properties. Journal of Clinical Child Psychology 2001;30:376-84.
114. Foa EB, Hembree E, Rothbaum BO. Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences Therapist Guide. Oxford University Press, 2007.
115. Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. British Journal of Psychiatry 2006;188:305-12.
116. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Archives of General Psychiatry 1989;46:1006-11.
117. Greenland S. Interpretation and choice of effect measures in epidemiologic analyses. American Journal of Epidemiology 1987;125(5):761-8.
118. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. National Institute of Health, 1976.
119. Higgins JTP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(6):557-60.
120. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Reviewers Handbook 5.0.0 [updated February] Section 8;. Chichester, UK: John Wiley & Sons, Ltd., 2008.
121. Higgins JPT, Deeks JJ, Altman DG. Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Reviewers Handbook 5.0.0 [updated February] Section 16. Chichester, UK: John Wiley & Sons, Ltd, 2008.
122. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society) 2009 Jan;172(1):137-59.
123. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.
124. Hofmann SG, Sawyer AT, Korte KJ, Smits JAJ. Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review. International Journal of Cognitive Therapy 2009;2:160-75.
125. Hofmann SG, Smits JA, Asnaani A, Gutner CA, Otto MW. Cognitive Enhancers for Anxiety Disorders. Pharmacology Biochemistry and Behavior 2011;99(2):275-84.
126. Hofmann SG. d-Cycloserine for treatment of anxiety disorders - making good exposures better and bad exposures worse. Depression and Anxiety 2014 March;31(3):175-7.
127. Hofmann SG, Otto MW, Pollack MH, Smits JA. d-Cycloserine Augmentation of Cognitive Behaviour Therapy for Anxiety disorders: an update. Current Psychiatry Reports 2015;17:532.
128. Jenike MA. Clinical practice. Obsessive-compulsive disorder. New England Journal of Medicine 2004;350(3):259-65.
129. Jones R, Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: CD003153]
130. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 1994;51(1):8-19.
131. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005;62(6):593-602.
132. Klorman R, Weerts TC, Hastings JE, Melamed BG, Lang PG. Psychometric description of some specific fear questionnaires. Behavior Therapy 1974;5(3):401-9.
133. Kovacs M. Childrens Depression Inventory Manual. New York: Multi-Health Systems, 1992.
134. Ledgerwood L, Richardson R, Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. Behavioral Neuroscience 2003;117(2):341-9.
135. Ledgerwood L, Richardson R, Cranney J. D-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction. Biological Psychiatry 2005;57(8):841-7.
136. Lee H, Kim JJ. Amygdalar NMDA receptors are critical for new fear learning in previously fear-conditioned rats. The Journal of Neuroscience 1998;18(20):8444-54.
137. Lee JL, Milton AL, Everitt BJ. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. The Journal of Neuroscience 2006;26(39):10051-6.
138. Liebowitz MR. Social phobia. Modern Problems in Pharmacopsychiatry 1987;22:141-73.
139. Liebowitz MR, Schneier FR, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phenelzinevs atenolol in social phobia: a placebo-controlled comparison. Archives of General Psychiatry 1992;49:290-300.
140. March JS, Parker JD, Sullivan K, Stallings P, Conners CK. The Multidimensional Anxiety Scale for Children: Factor structure, reliability, and validity. Journal of the American Academy of Child and Adolescent Psychiatry 1997;36:554-65.
141. Marks IM, Swinson RP, Başoglu M, Kuch K, Noshirvani H, O'Sullivan G, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. British Journal of Psychiatry 1993;162:776-87.
142. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. American Journal of Psychiatry 2000;157(5):669-82.
143. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. Journal of Affective Disorders 2005 Sept;88(1):27-45.
144. Murray CJL, Lopez AD. Measuring the Global burden of disease. New England Journal of Medicine 2013;369:448-57.
145. NICE Generalised Anxiety Disorder and Panic Disorder (With Or Without Agoraphobia) in Adults: Management in Primary, Secondary and Community Care. NICE clinical guideline 113. Available at www.nice.org.uk/CG113[NICE guideline] 2011;113.
146. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry 2008;63(12):1118-26.
147. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, et al. Treatment non-response in OCD: methodological and operational definitions. International Journal of Neuropsychopharmacology 2002;5:181-91.
148. Quirk GJ, Russo GK, Barron JL, Lebron K. The role of ventromedial prefrontal cortex in the recovery of extinguished fear. The Journal of Neuroscience Aug 15;20(16):6225-31.
149. Rapee RM, Abbott MJ, Baillie AJ, Gaston JE. Treatment of social phobia through pure self help and therapist-augmented self help. British Journal of Psychiatry 2007;191:246-52.
150. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and anxiety November 2000;12 Suppl 1:2-19.
151. Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learning and Memory 2004;11(5):510-6.
152. Rodrigues H, Figueira I, Lopes A, Gonçalves R, Mendlowicz MV, Coutinho ESF, Ventura P. Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PLOS ONE July 2014.
153. Rothbaum BO, Davis M. Applying learning principles to the treatment of post-trauma reactions. Annals of the New York Academy of Sciences Dec 2003;1008:112-21.
154. Scahill L, Riddle MA, McSwiggan-Hardin MT, et al. The Childrens Yale-Brown Obsessive-Compulsive Scale: preliminary report of reliability and validity. JAACAP 1997;36:844-53.
155. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Interpreting results and drawing conclusions. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
156. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. New England Journal of Medicine 1993;328:1398-405.
157. Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, 1970.
158. Sulkowski ML, Geller DA, Lewin AB, Murphy TK, Mittleman A, Brown A, Storch EA. The future of D-cycloserine and other cognitive modifiers in obsessive - compulsive and related disorders. Current Psychiatry Reviews 2014;10(4):317-24.
159. Szapiro G, Vianna MR, McGaugh JL, Medina JH, Izquierdo I. The role of NMDA glutamate receptors, PKA, MAPK, and CAMKII in the hippocampus in extinction of conditioned fear. Hippocampus 2003;13(1):53-8.
160. Thompson SG. Why sources of heterogeneity in meta analysis should be investigated. BMJ 1994;309(6965):1351-5.
161. Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: CD003730]
162. Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle. Journal of Neuroscience 2002;22:2343-51.
163. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. World Health Organization 1993.
164. Yang YL, Lu KT. Facilitation of conditioned fear extinction by d-cycloserine is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase cascades and requires de novo protein synthesis in basolateral nucleus of amygdala. Neuroscience 2005;134(1):247-60.
165. Yates RW, David Bienenfeld D, Bessman E, Brenner B, Daniels C, Erickson M, Friedman S. Anxiety Disorders. Medscape Emedicine January 2012.